Search company, investor...
Aura Biosciences company logo

Aura Biosciences

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Aura Biosciences

Aura Biosciences (NASDAQ: AURA) is a biotechnology company that develops therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates.

Headquarters Location

85 Bolton St.

Cambridge, Massachusetts, 02140,

United States


Missing: Aura Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aura Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aura Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aura Biosciences is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aura Biosciences Patents

Aura Biosciences has filed 14 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Diseases of the eye and adnexa
  • Vaccines
patents chart

Application Date

Grant Date


Related Topics




Vaccines, Diseases of the eye and adnexa, Transcription factors, Vaccination, Proteins


Application Date


Grant Date



Related Topics

Vaccines, Diseases of the eye and adnexa, Transcription factors, Vaccination, Proteins



Latest Aura Biosciences News

Aura Biosciences to Participate in Upcoming Investor Conferences

May 24, 2023

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: TD Cowen 4th Annual Oncology Innovation Summit on Tuesday, May 30, 2023. Fireside Chat at 10:00 a.m. ET. Jefferies Healthcare Conference on Thursday, Jun

Aura Biosciences Frequently Asked Questions (FAQ)

  • When was Aura Biosciences founded?

    Aura Biosciences was founded in 2009.

  • Where is Aura Biosciences's headquarters?

    Aura Biosciences's headquarters is located at 85 Bolton St., Cambridge.

  • What is Aura Biosciences's latest funding round?

    Aura Biosciences's latest funding round is IPO.

  • How much did Aura Biosciences raise?

    Aura Biosciences raised a total of $229.11M.

  • Who are the investors of Aura Biosciences?

    Investors of Aura Biosciences include Ysios Capital Partners, Lundbeckfond Ventures, Chiesi Ventures, Arix Bioscience, Advent Life Sciences and 17 more.

  • Who are Aura Biosciences's competitors?

    Competitors of Aura Biosciences include Catalent, Intercell, Glide Pharma, Pacira Biosciences, Azaya Therapeutics and 11 more.

Compare Aura Biosciences to Competitors

FORMAC Pharmaceuticals N.V.

FORMAC is a pharmaceutical R&D company engaged in drug delivery and development. The firm aims to increase pharmaceutical R&D productivity and product value by enhancing the performance of (pre)clinical drug candidates and marketed drugs.

Eratech srl

Eratech is a drug development company specialized in the field of inhalation drug delivery via nasal and pulmonary administration, for local and systemic therapies. Eratech offers to its clients the following selection of product development support services: Pharmacological-Toxicological, Pharmaceutical Development, Clinical Trials, Regulatory Affairs. nnn


Optotrack, Inc. is a high-tech company leading in the research and development of optical, imaging, chemical, as well as biological sensors and microsystems. The company is dedicated to commercializing its intellectual properties based on microfabrication and nanotechnology to seize rapidly growing market opportunities in the industries of healthcare, communication, and homeland security. Optotrack, Inc. offers a broad range of technology and business solutions from design through production to marketing and sales. The company combine decades of industry experience and R&D expertise in thin-film science, polymer engineering, solid-state sensing, digital imaging, optoelectronics, RF circuitry, medical diagnostics, microfluidics, and drug delivery to provide enabling technologies to the company's partners, customers, and community. The firm aims to deliver products and services of exceptional quality to cast the future, to improve the life quality for everyone.


CapsuTech is a product driven company focused on research and development of semi-natural, peptide-based, polymers for drug targeting and encapsulation of various chemical and biological entities. Such entities might be drugs, cosmetics, vitamins, food additives, proteins, virions and even cells.nVarious combinations of CapsuTech's modified amino-acid building-blocks provide high-diversity population of polymers and thus enable to formulate almost all molecules and to meet wide spectrum of needs. Such needs include targeting, site-specific release, controlled release. Other characteristics include protection from pH, enzyme proteolysis, oxidation, light and other damaging factors.

Kucera Pharmaceutical Company

Kucera Pharmaceutical Company is based in Winston-Salem, NC. The company started with a drug delivery approach that combined or conjugated delivery molecules with therapeutic molecules as a platform technology, both to improve the properties of the attached therapeutic molecules (making them orally available and improving distribution) and to extend patent life.


utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.�MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.